Chester County News and Community Website
Headquartered in Berwyn, PA, Annovis Bio, Inc. (NYSE: ANVS) is a clinical-stage, drug platform company addressing neurodegeneration, such as Alzheimer’s disease (AD), Parkinson’s disease (PD) and Alzheimer’s in Down Syndrome (AD-DS).
MALVERN, PA — Annovis Bio, Inc. (NYSE: ANVS) has scheduled a live investor webcast for December 11, 2024, at 4:30 PM EST. The event will feature critical updates on the …
Annovis Bio Announces Investor Webcast to Share Key Updates Read More MALVERN, PA — Annovis Bio, Inc. (NYSE: ANVS) announced its financial results for the third quarter ending September 30, 2024, alongside significant progress in its Alzheimer’s treatment pipeline.
Annovis Bio Advances Alzheimer’s Treatment with Phase 3 Trials and Financial Updates Read More MALVERN, PA — Annovis Bio Inc. (NYSE: ANVS) has announced the appointment of Matthew Peterson, Ph.D., as Senior Clinical Scientist. Dr. Peterson’s role will be pivotal in ensuring the medical, …
Annovis Bio Welcomes New Senior Clinical Scientist to Lead Key Studies Read More MALVERN, PA — Annovis Bio Inc. (NYSE: ANVS) has announced a successful outcome from its recent End-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA). The FDA has given …
Annovis Bio Advances Alzheimer’s Treatment with FDA Approval for Phase 3 Trials Read More MALVERN, PA — Annovis Bio Inc. (NYSE: ANVS) has made strides in the fight against neurodegenerative diseases with the filing of three new patents. These cover novel combination therapies involving their …
Annovis Bio Files Patents for Innovative Therapies in Neurodegenerative Disease Treatment Read More MALVERN, PA — Annovis Bio Inc. (NYSE: ANVS) has announced its financial results for the second quarter ending June 30, 2024, along with significant business updates. The company highlighted positive …
Annovis Bio Reports Q2 2024 Financial Results and Business Progress Read More MALVERN, PA — Annovis Bio Inc. (NYSE: ANVS) announced new preclinical data showing the positive combined effects of its lead compound, buntanetap, with the GLP-1 agonist dulaglutide (Trulicity®) in an …
Annovis Bio Shows Synergistic Effect of Buntanetap and Dulaglutide in Alzheimer’s Treatment Read More MALVERN, PA — Annovis Bio Inc. (NYSE: ANVS) has made a significant leap in the field of neurodegenerative disease treatment with the issuance of a U.S. patent for its lead …
Annovis Bio Secures Patent for Landmark TBI Treatment Read More MALVERN, PA — Annovis Bio Inc. (NYSE: ANVS) has received approval from the U.S. Food and Drug Administration (FDA) to transition to a new solid form of buntanetap in future …
Annovis Bio Gains FDA Approval for New Form of Neurodegenerative Drug Read More MALVERN, PA — Annovis Bio Inc. (NYSE: ANVS) has significantly bolstered its executive team by welcoming four industry professionals to its ranks. The move highlights Annovis’s efforts to innovative leadership …
Annovis Bio Boosts Executive Team with Four Industry Veterans Read More